Doximity IncAI investment squeeze reduces EBITDA margins from 55% to 49%

Doximity is accelerating artificial intelligence investments to expand beyond its core physician engagement platform, even as a sluggish pharmaceutical advertising market and rising costs pressure near-term financial performance. The company has signed its first AI Search contracts with top-20 pharmaceutical companies and believes AI Search alone represents a multibillion-dollar incremental addressable market, while nearly half of all active prescribers now use its AI tools. However, management expects the overall healthcare professional digital advertising market to grow only around 5% or less during fiscal 2027, and adjusted EBITDA margins are projected to decline from 55% in fiscal 2026 to approximately 49% in fiscal 2027 due to increased spending on AI compute, engineering talent, and marketing. The Zacks Consensus Estimate for fiscal 2027 revenues is pegged at $670.2 million, implying growth of 3.9%, while adjusted EPS is pinned at $1.39, indicating a decline of 8.6%. Shares of the Zacks Rank #3 company have lost 49.8% so far this year, compared with the industry's 5.6% decline and the S&P 500's 10.9% rise.
Doximity IncAI investment squeeze reduces EBITDA margins from 55% to 49%
Alcon AG
Cardinal Health Inc
Intuitive Surgical Inc